Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Leiomyoma 4Papillomavirus Infections 3Inflammation 2Frailty 2Uterine Cervical Dysplasia 1Triple Negative Breast Neoplasms 1Squamous Intraepithelial Lesions 1Radiodermatitis 1Prostatic Neoplasms 1Papilloma 1Liver Neoplasms 1Liver Cirrhosis 1Fibrosis 1Esophageal Neoplasms 1Deglutition Disorders 1Colonic Neoplasms 1Carcinoma, Hepatocellular 1Atypical Squamous Cells of the Cervix 1

Interventions

Sorafenib 61Bevacizumab 42Oxaliplatin 24Doxorubicin 22Radiosurgery 20Gemcitabine 20Fluorouracil 20Nivolumab 19durvalumab 18Radiofrequency Ablation 18pembrolizumab 17Capecitabine 17lenvatinib 16Cisplatin 16atezolizumab 13Leucovorin 13Radiotherapy 11tremelimumab 10Cyclophosphamide 10Carboplatin 10Irinotecan 9Ipilimumab 9Drug Therapy 9Everolimus 8Cryosurgery 8toripalimab 7fludarabine 7Sunitinib 7Chemotherapy, Adjuvant 7Melphalan 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Liver Neoplasms × epigallocatechin gallate × Clear all
NCT06015022 2025-09-05

CATCH-B

University of Texas Southwestern Medical Center

Phase 2 Recruiting
60 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Cirrhosis, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡